KLOW Peptide Blend (BPC-157, TB-500, GHK-Cu, KPV)

What Is the KLOW Peptide Blend?

KLOW is the GLOW blend with a fourth peptide added. GLOW combines BPC-157, TB-500 and GHK-Cu, three peptides studied mainly in tissue-repair and skin-remodeling models. KLOW adds KPV, which brings an inflammation-research angle to the same vial. The “K” is generally read as a nod to KPV. For a full side-by-side, read KLOW vs GLOW.

Each component has a separate research background. BPC-157 is a 15-amino-acid synthetic peptide based on a sequence from a human gastric juice protein, studied largely in animal models of gut and soft-tissue repair. TB-500 is a synthetic peptide derived from thymosin beta-4, the actin-binding protein linked to cell migration; see BPC-157 vs TB-500. GHK-Cu is the copper complex of the tripeptide glycyl-histidyl-lysine, first isolated from human plasma by Dr. Loren Pickart in 1973 and studied for decades in skin and wound-remodeling research; see what is GHK-Cu.

KPV is by far the smallest component. It matches the last three amino acids of alpha-MSH and has been studied on its own in cell and rodent models of intestinal and skin inflammation. Combining it with the other three reflects their separate, non-overlapping research areas, not evidence from a study of the blend itself.

This product is strictly for research purposes only. Not approved for human or animal use.

Key Characteristics

Component Profile

Blend Physical Properties

KLOW Components in Published Research

KPV is the component that sets KLOW apart. Most published KPV work comes from cell studies and rodent models of intestinal inflammation, with additional work on skin cells. Researchers study it because it carries part of the anti-inflammatory activity associated with alpha-MSH in a much smaller molecule.

The other three components have larger literatures. BPC-157 research centers on animal models of gut lining and soft-tissue repair, including blood vessel formation. Thymosin beta-4 research centers on actin binding and cell migration during wound closure. GHK-Cu research spans decades of skin, collagen and wound-remodeling studies, including wide use in cosmetic science.

Three of KLOW’s components were reviewed by the FDA’s compounding advisory panel in July 2026: BPC-157, TB-500 and KPV were each recommended by an 8-to-6 vote. That concerns pharmacy compounding, not research materials, and the FDA has not yet acted on it. Injectable GHK-Cu is scheduled for the panel’s next meeting; see the FDA’s next peptide review.

Frequently Asked Questions

What is in the KLOW blend?

80 mg of lyophilized peptide: BPC-157 (10 mg), TB-500 (10 mg), GHK-Cu (50 mg) and KPV (10 mg).

How is KLOW different from GLOW?

KLOW adds a fourth peptide, KPV, and has a higher total weight. GLOW contains BPC-157, TB-500 and GHK-Cu only. Compare the GLOW blend and the two-peptide WOLVERINE blend.

What does KPV add to the blend?

KPV is a tripeptide from the end of alpha-MSH, studied on its own in preclinical inflammation models. It adds an inflammation-research angle to the tissue-repair focus of the other three peptides.

Has the four-peptide blend been studied as a whole?

No. Each peptide has independent research; the combination has not been evaluated as a single formulation in published studies.

Why does KLOW have a blue tint?

The color comes from GHK-Cu, which is a copper complex. A light blue tint is expected.

How should KLOW be stored?

Refrigerated at 2–8 °C (36–46 °F), sealed, dry and away from light. For long-term storage, −20 °C. The lot COA should confirm all four components; here’s what to look for on a blend COA.